astemizole has been researched along with uk 68798 in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (64.71) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Keserü, GM | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Boyd, H; Boyd, JG; Deacon, M; Groot, MJ; Nettleton, DO; Price, D; Singleton, DH; Steidl-Nichols, JV; Troutman, MD; Wallace, NK; Williams, C | 1 |
| Bianucci, AM; Calderone, V; Coi, A; Massarelli, I; Testai, L | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Tytgat, J; Ulens, C | 1 |
| Annunziato, L; Cataldi, M; Di Renzo, G; Giorgio, G; Secondo, A; Taglialatela, M; Valore, M | 1 |
| Contreras-Jurado, C; Furini, S; García-Ferreiro, R; Gómez-Varela, D; Pardo, LA; Stühmer, W | 1 |
| Clancy, CE; Romero, L; Saiz, J; Trenor, B; Yang, PC | 1 |
| Becker, N; Brinkwirth, N; Doi, M; Fertig, N; Friis, S; Furukawa, H; Hasegawa, Y; Obergrussberger, A; Ohtsuki, A; Oka, T; Stoelzle-Feix, S; Takasuna, K | 1 |
17 other study(ies) available for astemizole and uk 68798
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
Topics: Cell Line; Cell Membrane Permeability; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluorescent Dyes; Humans; Indoles; Ligands; Models, Molecular; Patch-Clamp Techniques; Phenethylamines; Potassium Channel Blockers; Protein Binding; Structure-Activity Relationship; Sulfonamides | 2007 |
Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation.
Topics: Amino Acid Sequence; Heart; Humans; Models, Molecular; Molecular Sequence Data; Molecular Structure; Protein Subunits; Sequence Alignment; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation.
Topics: Animals; Astemizole; Cation Transport Proteins; DNA-Binding Proteins; Electric Conductivity; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Gene Expression; Humans; Microelectrodes; Mutation; Oocytes; Oxidation-Reduction; Patch-Clamp Techniques; Phenethylamines; Potassium Channels; Potassium Channels, Voltage-Gated; Sulfonamides; Terfenadine; Trans-Activators; Transcriptional Regulator ERG; Transfection; Xenopus | 2000 |
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells.
Topics: Animals; Anti-Arrhythmia Agents; Astemizole; Biological Transport; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Cation Transport Proteins; Cells, Cultured; Cetirizine; Electrophysiology; Ether-A-Go-Go Potassium Channels; Histamine H1 Antagonists; Hydroxyzine; Large-Conductance Calcium-Activated Potassium Channels; Nimodipine; Phenethylamines; Pituitary Gland; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Calcium-Activated; Potassium Channels, Voltage-Gated; Rats; Small-Conductance Calcium-Activated Potassium Channels; Sulfonamides; Terfenadine | 2000 |
Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide.
Topics: Astemizole; Benzopyrans; Ether-A-Go-Go Potassium Channels; Humans; Imipramine; Ion Channel Gating; Models, Molecular; Phenethylamines; Piperidines; Point Mutation; Potassium Channel Blockers; Structure-Activity Relationship; Sulfonamides | 2006 |
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Topics: Action Potentials; Anti-Arrhythmia Agents; Astemizole; Cisapride; Computer Simulation; Gene Expression; Genetic Predisposition to Disease; Heart Ventricles; Humans; Ion Channel Gating; Kinetics; Long QT Syndrome; Models, Statistical; Mutation; Phenethylamines; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Protein Conformation; Severity of Illness Index; Sotalol; Sulfonamides; Terfenadine | 2014 |
Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment.
Topics: Animals; Arrhythmias, Cardiac; Astemizole; Benchmarking; Calibration; Cardiovascular Agents; Cell Line; CHO Cells; Cricetulus; Drug Discovery; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Heart; HEK293 Cells; Humans; Patch-Clamp Techniques; Phenethylamines; Polypropylenes; Polytetrafluoroethylene; Reference Standards; Reproducibility of Results; Sulfonamides; Terfenadine | 2020 |